Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables - Net for 4 consecutive years, with $40.0 million as the latest value for Q2 2025.

  • Quarterly Receivables - Net changed N/A to $40.0 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $40.0 million through Jun 2025, changed N/A year-over-year, with the annual reading at $15.0 million for FY2023, N/A changed from the prior year.
  • Receivables - Net for Q2 2025 was $40.0 million at Kymera Therapeutics, up from $15.0 million in the prior quarter.
  • The five-year high for Receivables - Net was $40.0 million in Q2 2025, with the low at $900000.0 in Q1 2021.
  • Average Receivables - Net over 3 years is $18.6 million, with a median of $15.0 million recorded in 2023.